{"id":"a13999ef-aa5f-58c7-9b7e-968b265d432f","stable_key":"7484635e-cc8f-5cd6-a978-6dc5775a7db5:berberine-masld-apob","predicate":"reduces","statement":"Apolipoprotein B fell by an additional 3.42 mg/dL with berberine versus placebo, a secondary endpoint.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"dee90fdc-9307-59e7-91ff-a74b8f47ac3c","mechanism_event_label":"A separate lipoprotein marker changed; cardiovascular events were not the outcome.","subject":{"id":"7bbe0633-b2f1-510f-adc0-3c4d0ddad05d","slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"},"object":{"id":"f746a287-c8a1-52d8-b477-fd4df2e1a70f","slug":"circulating-apolipoprotein-b-concentration","display_name":"Circulating apolipoprotein B concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"dee90fdc-9307-59e7-91ff-a74b8f47ac3c","stable_key":"7484635e-cc8f-5cd6-a978-6dc5775a7db5:berberine-masld-apob-event","event_type":"observed_intervention","label":"A separate lipoprotein marker changed; cardiovascular events were not the outcome.","description":"Apolipoprotein B fell by an additional 3.42 mg/dL with berberine versus placebo, a secondary endpoint.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"7bbe0633-b2f1-510f-adc0-3c4d0ddad05d","slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f746a287-c8a1-52d8-b477-fd4df2e1a70f","slug":"circulating-apolipoprotein-b-concentration","display_name":"Circulating apolipoprotein B concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/berberine-research/41543854.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021\", \"start_char\": 0, \"end_char\": 2354, \"text_sha256\": \"1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Multicenter double-blind randomized placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Berberine 1 g/day for six months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Berberine research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"berberine","display_name":"Berberine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"337 diabetes-free adults with obesity and MASLD in China","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A separate lipoprotein marker changed; cardiovascular events were not the outcome.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"CT visceral adipose area and liver fat; lipid endpoints","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5edc30fe-aaae-577b-bd77-607fe97b789e","evidence_kind":"source_excerpt","locator":"Lines 1286-1297","start_line":1286,"end_line":1297,"excerpt":"### berberine-masld-apob\nApolipoprotein B fell by an additional 3.42 mg/dL with berberine versus placebo, a secondary endpoint.\nCondition category: normal\nnutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A separate lipoprotein marker changed; cardiovascular events were not the outcome.\norganism: 337 diabetes-free adults with obesity and MASLD in China\ntissue_or_cell_type: CT visceral adipose area and liver fat; lipid endpoints\nexperimental_model: Multicenter double-blind randomized placebo-controlled trial\nlimitations: No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup.\nexposure: Berberine 1 g/day for six months\nevidence_span: {\"source_cache\": \"artifacts/berberine-research/41543854.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021\", \"start_char\": 0, \"end_char\": 2354, \"text_sha256\": \"1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021\"}\n[berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152","model_system":"Multicenter double-blind randomized placebo-controlled trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9bb61e1d-e5cf-5b05-a9ca-409291f7a313","stable_key":"import-7484635e-cc8f-5cd6-a978-6dc5775a7db5","title":"Berberine: metabolism, nutrient connections and drug interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"2f376a035ae79c93e62e2ea4a8d5385643bf16553f108d12b6a80c89e6d41f4c","revision_id":"2a099429-1c4a-55be-aa2c-0565d08bda80","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}